Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 3/20 | 0.31 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17659928 | 0.74 | ACHE (0.33) | CYP3A4TSHRMAPK1ACHE | |
| SCHEMBL5397520 | 0.68 | CYP1A2 (0.42) | CYP3A4TSHRALDH1A1ACHEHSD17B10 | |
| SCHEMBL21962356 | 0.66 | ACHE (0.44) | MAPK1ACHE | |
| SCHEMBL15471190 | 0.65 | DRD4 (0.39) | CYP3A4TSHRNOS3NOS1NOS2 | |
| SCHEMBL19791798 | 0.65 | MEN1 (0.43) | MAPK1NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL4822580 | 0.65 | ACHE (0.36) | CYP3A4TSHRMAPK1NOS3NOS1 | |
| SCHEMBL32370030 | 0.64 | — | — | |
| SCHEMBL16127181 | 0.64 | CYP3A4 (0.40) | CYP3A4TSHRMAPK1CD44ALDH1A1 | |
| SCHEMBL10211899 | 0.64 | — | — | |
| SCHEMBL19791846 | 0.64 | MEN1 (0.46) | TSHRMAPK1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230031-B2 | Thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1471049-A1 | NOVEL THYROID HORMONE RECEPTOR LIGAND, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085541-A1 | Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof | TSHR, THRA, THRB | CYP3A4 1714/4885TSHR 1/4885MAPK1 3226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.